Clinical Outcome of Rituximab-Based Therapy (RCHOP) in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement

• DOI: 10.4143/crt.2013.45.2.112
• Publication Date: 2013-07-13T07:21:35Z
• Authors: Byung Woog Kang; Joon Ho Moon; Yee Soo Chae; Soo Jung Lee; Jong Gwang Kim; Yeo-Kyeoung Kim; Je-Jung Lee; Deok-Hwan Yang; Hyeoung-Joon Kim; Jin Young Kim; Young Rok Do; Keon Uk Park; Hong Suk Song; Ki Young Kwon; Min Kyung Kim; Kyung Hee Lee; Myung Soo Hyun; Hun Mo Ryoo; Sung Hwa Bae; Hwak Kim; Sang Kyun Sohn
• Keywords: Univariate analysis; International Prognostic Index

We investigated the clinical outcome of bone marrow (BM) involvement in patients with diffuse large B-cell lymphoma (DLBCL) who received rituximab-based therapy.A total 567 consecutive newly diagnosed DLBCL treated rituximab-CHOP (RCHOP) between November 2001 and March 2010 were included current study. All underwent a BM study at initial staging characteristics prognosis these or without analyzed retrospectively.The cohort patients. The overall incidence was 8.5%. With median follow-up duration 33.2 months (range, 0.1 to 80.7 months) for alive last follow-up, five-year survival (OS) event-free (EFS) rate (76.3% 67.5%, p<0.001) statistically higher than that (44.3% 40.1%, p<0.001). In multivariate analysis, among patients, showed significant association OS EFS. univariate analyses, even stage IV worse EFS observed group.BM diagnosis affected RCHOP. Although use RCHOP can result improvement therapeutic effect DLBCL, is still negative prognostic factor era rituximab.